Tau epitope and binding molecules
AssigneeGen2 Neuroscience Limited
InventorsFrederick John Livesey, Clare Jones
Life of this patent
Estimating the term…
Abstract
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Claims20
An antibody or antigen-binding fragment thereof, comprising an antigen-binding site comprising HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of antibody:
- (a) Clone 1 of SEQ ID NO:
- 14, SEQ ID NO:
- 15,
- SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18 and
- SEQ ID NO:
- 19;
- (b) Clone 2 of SEQ ID NO:
- 20, SEQ ID NO:
- 21,
- SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24 and
- SEQ ID NO:
- 25;
- (c) Clone 3 of SEQ ID NO:
- 26, SEQ ID NO:
- 27,
- SEQ ID NO:
- 28, SEQ ID NO:
- 29, SEQ ID NO:
- 30 and
- SEQ ID NO:
- 31;
- (d) Clone 4 of SEQ ID NO:
- 32, SEQ ID NO:
- 33,
- SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36 and
- SEQ ID NO:
- 37;
- (e) Clone 5 of SEQ ID NO:
- 38, SEQ ID NO:
- 39,
- SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42 and
- SEQ ID NO:
- 43;
- (f) Clone 6 of SEQ ID NO:
- 44, SEQ ID NO:
- 45,
- SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 48 and
- SEQ ID NO:
- 49;
- (g) Clone 7 of SEQ ID NO:
- 50, SEQ ID NO:
- 51,
- SEQ ID NO:
- 52, SEQ ID NO:
- 53, SEQ ID NO:
- 54 and
- SEQ ID NO:
- 55;
- (h) Clone 8 of SEQ ID NO:
- 56, SEQ ID NO:
- 57,
- SEQ ID NO:
- 58, SEQ ID NO:
- 59, SEQ ID NO:
- 60 and
- SEQ ID NO:
- 61;
- (i) Clone 9 of SEQ ID NO:
- 62, SEQ ID NO:
- 63,
- SEQ ID NO:
- 64, SEQ ID NO:
- 65, SEQ ID NO:
- 66 and
- SEQ ID NO:
- 67;
- (j) Clone 10 of SEQ ID NO:
- 68, SEQ ID NO:
- 69,
- SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72 and
- SEQ ID NO:
- 73;
- (k) Clone 11 of SEQ ID NO:
- 74, SEQ ID NO:
- 75,
- SEQ ID NO:
- 76, SEQ ID NO:
- 77, SEQ ID NO:
- 78 and
- SEQ ID NO:
- 79;
- (l) Clone 12 of SEQ ID NO:
- 80, SEQ ID NO:
- 81,
- SEQ ID NO:
- 82, SEQ ID NO:
- 83, SEQ ID NO:
- 84 and
- SEQ ID NO:
- 85;
- (m) Clone 13 of SEQ ID NO:
- 86, SEQ ID NO:
- 87,
- SEQ ID NO:
- 88, SEQ ID NO:
- 89, SEQ ID NO:
- 90 and
- SEQ ID NO:
- 91;
- (n) Clone 14 of SEQ ID NO:
- 92, SEQ ID NO:
- 93,
- SEQ ID NO:
- 94, SEQ ID NO:
- 95, SEQ ID NO:
- 96 and
- SEQ ID NO:
- 97;
- (o) Clone 15 of SEQ ID NO:
- 98, SEQ ID NO:
- 99,
- SEQ ID NO:
- 100, SEQ ID NO:
- 101, SEQ ID NO:
- 102
- and SEQ ID NO:
- 103;
- (p) Clone 16 of SEQ ID NO:
- 104, SEQ ID NO:
- 105,
- SEQ ID NO:
- 106, SEQ ID NO:
- 107, SEQ ID NO:
- 108
- and SEQ ID NO:
- 109;
- or
- (q) Clone 17 of SEQ ID NO:
- 110, SEQ ID NO:
- 111,
- SEQ ID NO:
- 112, SEQ ID NO:
- 113, SEQ ID NO:
- 114
- and SEQ ID NO:
- 115;
- wherein the sequences are defined according to Kabat nomenclature.
A method of making an isolated antibody or antigen-binding fragment thereof comprising culturing the host cell of 11 in conditions suitable for expression of the isolated antibody or antigen-binding fragment thereof, expressing the antibody or antigen-binding fragment thereof and isolating the expressed antibody or antigen-binding fragment thereof.
Dependencies are inferred from the claim text.